Nanocell Therapeutics

Our goal is to revolutionize current cell and gene therapy practices by eliminating the need for ex-vivo cell manipulations. At NanoCell we develop in vivo gene therapies harnessing our non-viral, DNA-based, cell directed, technology platform. Our goal is to transform the cell and gene therapy field by converting adoptive cell therapies into gene therapies. Ultimately, we are committed to ensuring patients have access to exceptional therapeutic options worldwide. While many in the field focus on viral or RNA-based methods, we uniquely harness the lasting potential of DNA, delivered through our advanced non-viral vector technology. At NanoCell, we unite top talent and experts deeply anchored in science, spanning from multidisciplinary research to drug development, as well as corporate and business leadership. Geerlings is an experienced executive and serial entrepreneur who has co-founded and led multiple successful biotech companies . Hrubiec is a distinguished intellectual property attorney, as well as a Ph.D.